These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37846549)

  • 1. Evaluation of pentamidine tolerability and efficacy between
    Koon A; He J; Patel J; Morse A; Boseman V; Hamilton A; Knight T; Shah N; Ragon B; Chojecki A; Ai J; Steuerwald N; Gerber J; Copelan E; Grunwald M; Arnall J
    Pharmacogenomics; 2023 Oct; 24(15):821-830. PubMed ID: 37846549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and tolerability of intravenous pentamidine for Pneumocystis carinii pneumonia prophylaxis in adult hematopoietic stem cell transplant patients: a retrospective study.
    Awad WB; Asaad A; Al-Yasein N; Najjar R
    BMC Infect Dis; 2020 Jun; 20(1):400. PubMed ID: 32503449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.
    Quinn M; Fannin JT; Sciasci J; Bragg A; Campbell PK; Carias D; Crews KR; Gregornik D; Jeha S; Maron G; Pauley JL; Swanson HD; Wolf J; Greene W
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866879
    [No Abstract]   [Full Text] [Related]  

  • 4. A retrospective study of intravenous pentamidine for Pneumocystis jirovecii pneumonia prophylaxis in adult patients with hematologic malignancies-its utility during respiratory virus pandemics.
    Liew YX; Ho AYL; Wong GC; Chung SJ; Tan TT; Tan BH
    Int J Infect Dis; 2024 Jun; 143():107059. PubMed ID: 38615824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
    Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
    Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumocystis jirovecii Pneumonia Prophylaxis with Intravenous Pentamidine in Adult Allogeneic Hematopoietic Stem Cell Transplant Patients.
    McCollam S; Lewis JS; Bubalo J; Diaz A
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0083322. PubMed ID: 36214573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous pentamidine for Pneumocystis carinii/jiroveci pneumonia prophylaxis in pediatric transplant patients.
    Clark A; Hemmelgarn T; Danziger-Isakov L; Teusink A
    Pediatr Transplant; 2015 May; 19(3):326-31. PubMed ID: 25712369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
    Evernden C; Dowhan M; Dabas R; Chaudhry A; Kalra A; Dharmani-Khan P; Gregson D; Johnson A; Jupp J; Jimenez-Zepeda V; Jamani K; Duggan P; Tay J; Khan F; Daly A; Storek J
    Cytotherapy; 2020 Jan; 22(1):27-34. PubMed ID: 31889628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Effectiveness of Intravenous Pentamidine for Prophylaxis of Pneumocystis jirovecii Pneumonia in Pediatric Hematology/Oncology Patients.
    Solodokin LJ; Klejmont LM; Scipione MR; Dubrovskaya Y; Lighter-Fisher J; Papadopoulos J
    J Pediatr Hematol Oncol; 2016 Aug; 38(6):e180-5. PubMed ID: 27164533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerodigestive adverse effects during intravenous pentamidine infusion for Pneumocystis jirovecii pneumonia prophylaxis.
    Savaşan S; George A; Sokolowski C; McGraw BJ; Rademacher H
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28714. PubMed ID: 32979296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration.
    Afrin LB; Afrin JB
    Clin Transplant; 2011; 25(3):E271-5. PubMed ID: 21299635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous pentamidine is safe and effective as primary pneumocystis pneumonia prophylaxis in children and adolescents undergoing hematopoietic stem cell transplantation.
    DeMasi JM; Cox JA; Leonard D; Koh AY; Aquino VM
    Pediatr Infect Dis J; 2013 Sep; 32(9):933-6. PubMed ID: 23538522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of intravenous pentamidine isethionate for Pneumocystis jiroveci prophylaxis in a pediatric oncology population.
    Orgel E; Rushing T
    Pediatr Infect Dis J; 2014 Mar; 33(3):319-21. PubMed ID: 24030353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safe and Effective Prophylaxis with Bimonthly Intravenous Pentamidine in the Pediatric Hematopoietic Stem Cell Transplant Population.
    Levy ER; Musick L; Zinter MS; Lang T; Cowan MJ; Weintrub PS; Dvorak CC
    Pediatr Infect Dis J; 2016 Feb; 35(2):135-41. PubMed ID: 26418240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adequacy to diagnostic recommendations in patients with Pneumocystis jirovecii pneumonia treated with intravenous pentamidine].
    Cantarelli L; Gutiérrez Nicolás F; Nazco Casariego GJ; García Gil S
    Rev Esp Quimioter; 2022 Feb; 35(1):30-34. PubMed ID: 34854660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant.
    Sweiss K; Anderson J; Wirth S; Oh A; Quigley JG; Khan I; Saraf S; Mactal-Haaf C; Rondelli D; Patel P
    Bone Marrow Transplant; 2018 Mar; 53(3):300-306. PubMed ID: 29269796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group.
    Dohn MN; Weinberg WG; Torres RA; Follansbee SE; Caldwell PT; Scott JD; Gathe JC; Haghighat DP; Sampson JH; Spotkov J; Deresinski SC; Meyer RD; Lancaster DJ
    Ann Intern Med; 1994 Aug; 121(3):174-80. PubMed ID: 7880228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
    Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
    J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia.
    O'Brien JG; Dong BJ; Coleman RL; Gee L; Balano KB
    Clin Infect Dis; 1997 May; 24(5):854-9. PubMed ID: 9142782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse effects associated with intravenous pentamidine isethionate as treatment of Pneumocystis carinii pneumonia in AIDS patients.
    Balslev U; Nielsen TL
    Dan Med Bull; 1992 Aug; 39(4):366-8. PubMed ID: 1526188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.